drugset
drugset / Trial / NCT04368182

AFP Specific T Cell Receptor Transduced T Cells Injection(C-TCR055) in Unresectable Hepatocellular Carcinoma

NCT04368182 ↗

Phase 1 Unknown 3 enrolled Zhejiang University
NaSingle-groupOpen-labelTreatment

Summary

A study that aimed to assess the safety and anti-tumor activity of C-TCR055 injection in unresectable HCC patients

Timeline

Start
2020-04-13
Primary completion
2020-08-31
Completion
2021-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject C-TCR055 Cell therapy — Intravenous

Indications

hepatocellular carcinoma